An augmented passive immune therapy to treat fulminant bacterial infections
- PMID: 20370679
- DOI: 10.2174/157489110791233496
An augmented passive immune therapy to treat fulminant bacterial infections
Abstract
In the early 1900s, passive immunization/antibody therapy was used to treat a variety of human ailments such as hypoimmunoglobulinemia, cancer and infectious disease. The advent of antibiotic therapy had relegated this type of therapy obsolete for treatment of infectious diseases. Emergence of multi-drug resistant pathogens along with novel monoclonal antibody production techniques has rekindled the interest in passive immunization (PI). An increase in the number of monoclonal antibody patent applications in the recent past suggests a renewed commercial interest in PI. Despite these developments, antibody therapy for infectious diseases has limitations including the need for large or frequent dosages. P4, a 28-amino acid peptide is a multi-lineage cellular activator. P4, along with infectious disease (i.e. Pathogen) specific immunoglobulin, has been shown in vitro and in vivo in mice to potentiate innate immunity. This review will discuss the progress made in passive antibody therapy, the challenges still to be surmounted, and the potential expanded role of an immune-potentiating peptide (bio-molecule) in the quest to utilize and revitalize passive immunization.
Similar articles
-
Preventing infectious disease with passive immunization.Microbes Infect. 2000 May;2(6):701-8. doi: 10.1016/s1286-4579(00)00355-5. Microbes Infect. 2000. PMID: 10884621 Review.
-
Passive antibody therapy for infectious diseases.Nat Rev Microbiol. 2004 Sep;2(9):695-703. doi: 10.1038/nrmicro974. Nat Rev Microbiol. 2004. PMID: 15372080 Review.
-
A case for passive immunoprophylaxis against tuberculosis.Lancet Infect Dis. 2006 Dec;6(12):813-8. doi: 10.1016/S1473-3099(06)70658-2. Lancet Infect Dis. 2006. PMID: 17123901
-
Evaluation of a novel therapeutic approach to treating severe pneumococcal infection using a mouse model.Clin Vaccine Immunol. 2009 Jun;16(6):806-10. doi: 10.1128/CVI.00120-09. Epub 2009 Apr 22. Clin Vaccine Immunol. 2009. PMID: 19386795 Free PMC article.
-
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Nat Rev Immunol. 2018 May;18(5):297-308. doi: 10.1038/nri.2017.148. Epub 2018 Jan 30. Nat Rev Immunol. 2018. PMID: 29379211 Free PMC article. Review.
Cited by
-
Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion.Front Med (Lausanne). 2020 Jul 28;7:435. doi: 10.3389/fmed.2020.00435. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32850916 Free PMC article.
-
Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods.Comput Methods Programs Biomed. 2020 Nov;196:105617. doi: 10.1016/j.cmpb.2020.105617. Epub 2020 Jun 20. Comput Methods Programs Biomed. 2020. PMID: 32593060 Free PMC article.
-
Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.Intern Emerg Med. 2020 Aug;15(5):819-824. doi: 10.1007/s11739-020-02384-2. Epub 2020 May 28. Intern Emerg Med. 2020. PMID: 32468508 Free PMC article.
-
The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms.Pathogens. 2020 Apr 29;9(5):331. doi: 10.3390/pathogens9050331. Pathogens. 2020. PMID: 32365466 Free PMC article. Review.
-
Is there any potential management against COVID-19? A systematic review and meta-analysis.Daru. 2020 Dec;28(2):765-777. doi: 10.1007/s40199-020-00367-4. Epub 2020 Aug 18. Daru. 2020. PMID: 32812187 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous